This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Figures released by NHSE show the NHS diagnosed over 11,000 more cancers in 2022, reaching a new record high level – with almost 950 people a day getting a diagnosis in England. By 2028, the NHS aims to diagnose 75% of cancers at stage 1 or 2. While there are many ways to treat cancer, one use is radiopharmaceuticals.
As well as radiopharmaceuticals being used for cancer treatment, they are also used in diagnostics for imaging tests, such as gamma-scintigraphy and PET scans to create pictures of the inside of the body. For example, a radiopharmaceutical can be used to visualise a tumour or assess lung function.
In diagnostics it enables visualisation of organs like the brain, heart, and bones to detect diseases such as cancer and cardiovascular conditions. In therapy it treats ailments directly by targeting radiation to specific tissue, minimising exposure to healthy tissue.
Our Radiopharmaceutical Products Framework Agreement provides quality assurance, ensuring that all products and services available comply with the latest regulations, mitigating risks and protecting customers and patients. ​
It provides radiopharmaceutical products, maintenance, support and training from a carefully selected range of qualified suppliers. It covers radiopharmaceutical kits, diagnostic and therapeutic radiopharmaceuticals. Also covered are a range of generators including technetium, krypton, and gallium.
Framework Agreement Information
What dates is the framework agreement active?
01 April 2021 – 31 March 2025
Who can take advantage of the framework agreement?
NHS and UK Public Sector organisations
What does this framework agreement cover?
It covers a wide range of radiopharmaceutical products including:
- radiopharmaceutical kits
- diagnostic radiopharmaceuticals
- therapeutic radiopharmaceuticals
- technetium generators
- krypton generators
- 18F -FDG
What are the benefits of using this framework agreement?
CONTINUITY OF SUPPLY
Ensures continuity of supply, so NHS organisations can place standing orders for scheduled deliveries with suppliers to ensure uninterrupted product coverage.
NEW SERVICES
Appointed suppliers will be able to bring forward new services throughout the life of the framework agreement.
SIMPLIFIED ORDERING PROCESS
Ability to view suppliers through GHX/NEXUS, which supports the ordering and payment process.
MEDICAL DEVICES DIRECTIVE 93/42/EEC
All products comply with the Medical Devices Directive 93/42/EEC.
SUPPORT PROVIDED
Suppliers can provide training, maintenance and support where required.
DELIVERY OPTIONS AVAILABLE
Direct delivery option to all approved organisations.
Customer Framework Agreement Portal
Access our framework agreement documentation via our Customer Framework Agreement Portal
Supplier Details
Contact the Health Category Team
"*" indicates required fields